-
A Phase 3 Open-Label Randomized Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
This study is being conducted to determine how safe and effective a drug called DZD9008 is compared to standard chemotherapy in patients with locally advanced ... -
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
This study is for patients with early-stage triple-negative breast cancer who received a treatment called pembrolizumab (a medicine used to treat melanoma). Some patients will ... -
Phase 3 study evaluating AMG 757 Tarlatamab for patients with Small Cell Lung Cancer
This study is for patients with small cell lung cancer (SCLC). They want to see if a new treatment called tarlatamab (an immunotherapy that might ... -
A Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
This is a study to see if a new medicine called epcoritamab (works by binding to CD3 and CD20 on cells, which brings T cells ...
-
AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
This study is about patients who have recently been diagnosed with early-stage classical Hodgkin lymphoma (cHL). The researchers want to compare two treatment approaches: one ...
-
A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFRmutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
This study is to see if a new medicine called AK112 can help patients with advanced non-squamous non-small cell lung cancer (NSCLC) that didn't ...